194 related articles for article (PubMed ID: 11972391)
1. Cellular glutathione content, in vitro chemoresponse, and the effect of BSO modulation in samples derived from patients with advanced ovarian cancer.
Lewandowicz GM; Britt P; Elgie AW; Williamson CJ; Coley HM; Hall AG; Sargent JM
Gynecol Oncol; 2002 May; 85(2):298-304. PubMed ID: 11972391
[TBL] [Abstract][Full Text] [Related]
2. Rapid development of drug resistance in human ovarian tumor xenografts after a single treatment with melphalan in Vivo.
Caffrey PB; Zhang Y; Frenkel GD
Anticancer Res; 1998; 18(4C):3021-5. PubMed ID: 9713503
[TBL] [Abstract][Full Text] [Related]
3. Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells.
Kisara S; Furusawa S; Murata R; Ogata M; Hikichi N; Takayanagi Y; Sasaki K
Oncol Res; 1995; 7(3-4):191-200. PubMed ID: 8555653
[TBL] [Abstract][Full Text] [Related]
4. Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian-carcinoma cell lines.
Mistry P; Loh SY; Kelland LR; Harrap KR
Int J Cancer; 1993 Nov; 55(5):848-56. PubMed ID: 8244583
[TBL] [Abstract][Full Text] [Related]
5. Augmentation of cisplatin (DDP) cytotoxicity in vivo by DL-buthionine sulfoximine (BSO) in DDP-sensitive and-resistant rat ovarian tumors and its relation to DNA interstrand cross links.
Chen G; Zeller WJ
Anticancer Res; 1991; 11(6):2231-7. PubMed ID: 1776864
[TBL] [Abstract][Full Text] [Related]
6. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
Vanhoefer U; Cao S; Minderman H; Toth K; Skenderis BS; Slovak ML; Rustum YM
Clin Cancer Res; 1996 Dec; 2(12):1961-8. PubMed ID: 9816155
[TBL] [Abstract][Full Text] [Related]
7. Lack of a role for MRP1 in platinum drug resistance in human ovarian cancer cell lines.
Sharp SY; Smith V; Hobbs S; Kelland LR
Br J Cancer; 1998 Jul; 78(2):175-80. PubMed ID: 9683290
[TBL] [Abstract][Full Text] [Related]
8. [Potentiation of cisplatin sensitivity of cisplatin-resistant human ovarian cancer cell lines by L-buthionine-S,R-sulfoximine].
Kudoh K; Kita T; Hirata J; Ishii K; Hiramatsu H; Kikuchi Y; Nagata I
Nihon Sanka Fujinka Gakkai Zasshi; 1994 Jun; 46(6):525-32. PubMed ID: 8040625
[TBL] [Abstract][Full Text] [Related]
9. Identification of multidrug resistance-associated protein 1 and glutathione as multidrug resistance mechanisms in human prostate cancer cells: chemosensitization with leukotriene D4 antagonists and buthionine sulfoximine.
van Brussel JP; Oomen MA; Vossebeld PJ; Wiemer EA; Sonneveld P; Mickisch GH
BJU Int; 2004 Jun; 93(9):1333-8. PubMed ID: 15180633
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of small-molecule chemosensitizers in reversal of cisplatin resistance in ovarian cancer cells.
Yellepeddi VK; Vangara KK; Kumar A; Palakurthi S
Anticancer Res; 2012 Sep; 32(9):3651-8. PubMed ID: 22993302
[TBL] [Abstract][Full Text] [Related]
11. Regulation of cellular glutathione modulates nuclear accumulation of daunorubicin in human MCF7 cells overexpressing multidrug resistance associated protein.
Benderra Z; Trussardi A; Morjani H; Villa AM; Doglia SM; Manfait M
Eur J Cancer; 2000 Feb; 36(3):428-34. PubMed ID: 10708946
[TBL] [Abstract][Full Text] [Related]
12. [Increasing chemosensitivity to cisplatin by glutathione depletion with buthionine sulfoximine. In vitro and in vivo studies with a human squamous cell cancer line].
Bier H
Laryngorhinootologie; 1990 Jan; 69(1):16-20. PubMed ID: 2310456
[TBL] [Abstract][Full Text] [Related]
13. Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells.
Lai SL; Hwang J; Perng RP; Whang-Peng J
Oncol Res; 1995; 7(1):31-8. PubMed ID: 7549042
[TBL] [Abstract][Full Text] [Related]
14. [Arsenic trioxide combined with buthionine sulfoximine enhances apoptosis in multidrug-resistant human leukemia K562/ADM cells in vitro].
Wang T; Ma LM; Zhang HP; Wang HW; Yang LH; Qiao ZH
Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):188-91. PubMed ID: 18756933
[TBL] [Abstract][Full Text] [Related]
15. N-acetylcysteine enhances multidrug resistance-associated protein 1 mediated doxorubicin resistance.
Akan I; Akan S; Akca H; Savas B; Ozben T
Eur J Clin Invest; 2004 Oct; 34(10):683-9. PubMed ID: 15473893
[TBL] [Abstract][Full Text] [Related]
16. Circumvention of drug resistance in cisplatin-resistant sublines of the human squamous carcinoma cell line HLac 79 in vitro and in vivo.
Bier H
Acta Otolaryngol; 1991; 111(4):797-806. PubMed ID: 1950544
[TBL] [Abstract][Full Text] [Related]
17. Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin.
Lau DH; Lewis AD; Ehsan MN; Sikic BI
Cancer Res; 1991 Oct; 51(19):5181-7. PubMed ID: 1717140
[TBL] [Abstract][Full Text] [Related]
18. Selective and synergistic activity of L-S,R-buthionine sulfoximine on malignant melanoma is accompanied by decreased expression of glutathione-S-transferase.
Fruehauf JP; Zonis S; al-Bassam M; Kyshtoobayeva A; Dasgupta C; Milovanovic T; Parker RJ; Buzaid AC
Pigment Cell Res; 1997 Aug; 10(4):236-49. PubMed ID: 9263331
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms and modulation of multidrug resistance in primary human renal cell carcinoma.
Mickisch GH; Roehrich K; Koessig J; Forster S; Tschada RK; Alken PM
J Urol; 1990 Sep; 144(3):755-9. PubMed ID: 1974934
[TBL] [Abstract][Full Text] [Related]
20. Modulation by D,L-buthionine-S,R-sulphoximine of etoposide cytotoxicity on human non-small cell lung, ovarian and breast carcinoma cell lines.
Mans DR; Schuurhuis GJ; Treskes M; Lafleur MV; Retèl J; Pinedo HM; Lankelma J
Eur J Cancer; 1992; 28A(8-9):1447-52. PubMed ID: 1325177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]